Koji Hanai

Summary

Affiliation: Dainippon Sumitomo Pharma Co
Country: Japan

Publications

  1. pmc Effects of atelocollagen formulation containing oligonucleotide on endothelial permeability
    Koji Hanai
    Formulation Research and Development Laboratories, Dainippon Sumitomo Pharma Co, Ltd, 1 3 45 Kurakakiuchi, Ibaraki shi, Osaka 567 0878, Japan
    J Drug Deliv 2012:245835. 2012
  2. ncbi request reprint Atelocollagen-mediated systemic DDS for nucleic acid medicines
    Koji Hanai
    Formulation Laboratories, Technology Research and Development Center, Dainippon Sumitomo Pharma Co, Ltd, Ibaraki, Osaka 567 0878, Japan
    Ann N Y Acad Sci 1082:9-17. 2006
  3. pmc Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo
    Yoshiko Minakuchi
    Formulation Research Laboratories, Sumitomo Pharmaceuticals Co Ltd, Osaka 567 0878, Japan
    Nucleic Acids Res 32:e109. 2004
  4. ncbi request reprint Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease
    Koji Hanai
    Formulation Research Laboratories, Sumitomo Pharmaceuticals Co, Ltd, Ibaraki shi, Osaka 567 0878, Japan
    Hum Gene Ther 15:263-72. 2004
  5. pmc Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
    Fumitaka Takeshita
    Section for Studies on Metastasis, National Cancer Center Research Institute, 1 1 Tsukiji 5 chome, Chuo Ku, Tokyo 104 0045, Japan
    Proc Natl Acad Sci U S A 102:12177-82. 2005
  6. ncbi request reprint Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity
    Takuji Ishimoto
    Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Mol Ther 16:387-95. 2008

Collaborators

  • Takahiro Ochiya
  • Takashi Kojima
  • Yoshifumi Takei
  • Shunji Nagahara
  • Fumitaka Takeshita
  • Yoshiko Minakuchi
  • Takuji Ishimoto
  • Kimi Honma
  • Akihiko Sano
  • Takashi Kato
  • Yusuke Yamamoto
  • Hideo Sasaki
  • Seiichi Matsuo
  • Kenji Kadomatsu
  • Yuzo Tarumi
  • Yukio Yuzawa
  • Kotaro Hirai
  • Takumi Teratani
  • Nachi Namatame
  • Masaaki Terada
  • Makiko Kouno
  • Nobuyoshi Kosaka

Detail Information

Publications6

  1. pmc Effects of atelocollagen formulation containing oligonucleotide on endothelial permeability
    Koji Hanai
    Formulation Research and Development Laboratories, Dainippon Sumitomo Pharma Co, Ltd, 1 3 45 Kurakakiuchi, Ibaraki shi, Osaka 567 0878, Japan
    J Drug Deliv 2012:245835. 2012
    ..These changes were induced through p38 MAP kinase signaling. It is important to elucidate the biological functions of atelocollagen in order to be able to exploit its drug delivery properties...
  2. ncbi request reprint Atelocollagen-mediated systemic DDS for nucleic acid medicines
    Koji Hanai
    Formulation Laboratories, Technology Research and Development Center, Dainippon Sumitomo Pharma Co, Ltd, Ibaraki, Osaka 567 0878, Japan
    Ann N Y Acad Sci 1082:9-17. 2006
    ..These results indicate the strong potential of the atelocollagen-mediated drug delivery system for practical therapeutic technology...
  3. pmc Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo
    Yoshiko Minakuchi
    Formulation Research Laboratories, Sumitomo Pharmaceuticals Co Ltd, Osaka 567 0878, Japan
    Nucleic Acids Res 32:e109. 2004
    ..Thus, for clinical applications of siRNA, an Atelocollagen-based non-viral delivery method could be a reliable approach to achieve maximal function of siRNA in vivo...
  4. ncbi request reprint Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease
    Koji Hanai
    Formulation Research Laboratories, Sumitomo Pharmaceuticals Co, Ltd, Ibaraki shi, Osaka 567 0878, Japan
    Hum Gene Ther 15:263-72. 2004
    ....
  5. pmc Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo
    Fumitaka Takeshita
    Section for Studies on Metastasis, National Cancer Center Research Institute, 1 1 Tsukiji 5 chome, Chuo Ku, Tokyo 104 0045, Japan
    Proc Natl Acad Sci U S A 102:12177-82. 2005
    ..Thus, for treatment of bone metastasis of prostate cancer, an atelocollagen-mediated systemic delivery method could be a reliable and safe approach to the achievement of maximal function of siRNA...
  6. ncbi request reprint Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity
    Takuji Ishimoto
    Department of Biochemistry, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Mol Ther 16:387-95. 2008
    ..This therapy had no adverse effects such as induction of interferon, or liver or renal damage. Our data indicate that the systemic delivery of siRNA targeting MCP-1 is a potent therapeutic strategy for CHS treatment...